SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells
OncoTargets and Therapy2018Vol. Volume 11, pp. 6811–6825
Citations Over Time
Abstract
As far as we know, our report is the first research that indicated the promotion of siRNA delivery via nanoparticles to gastric CICs and achievement of superior therapeutic effect against gastric CICs by utilization of CD44 antibody. Therefore, CD44-SATB1-ILs represent an up-and-coming approach for eliminating gastric CICs and also a promising treatment for therapy of gastric cancer.
Related Papers
- → The first soluble conjugated poly(2,6-anthrylene): synthesis and properties(2007)28 cited
- → The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells(2023)3 cited
- → The Interconnection of Two Positive Charges by Conjugation and Cross‐Conjugation in Bis‐Quinolinium Ethynyls(2019)8 cited
- → Carbon‐13 nuclear magnetic resonance spectroscopy of conjugated polyynes(1979)7 cited
- → ChemInform Abstract: Cycloadditions of 1,3,4‐Oxadiazin‐6‐ones (4,5‐Diaza‐α‐pyrones). Part 8. Conjugated and Non‐conjugated Cyclopentenones by a Reaction Cascade from Methyl 6‐Oxo‐5‐phenyl‐1,3,4‐oxadiazine‐2‐carboxylate and 1,3‐Butadienes.(1988)